

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

DIAGNOSTICS ASSESSMENT PROGRAMME

Equality impact assessment – Scoping

SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of bile acid diarrhoea

The impact on equality has been assessed during this assessment according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (scoping workshop discussion, assessment subgroup discussion), and, if so, what are they?

Potential equality issues were discussed both in the scoping workshop 22 October 2020 and in the assessment subgroup meeting 4 November 2020.

The following were identified as potential equality issues relating to the condition:

- People with chronic diarrhoea may be classified as having a disability and therefore be protected under the Equality Act 2010.
- IBS is twice as common in women as in men. It may be that the prevalence distribution of bile acid diarrhoea follows a similar pattern.
- Symptoms of bile acid diarrhoea often first appear between the age of 20 and 30 years.

The following were identified as potential equality issues relating to the testing:

- Less people from black, Asian and minority ethnic groups than expected are seen for investigation of bile acid diarrhoea.
- People who are pregnant, breast feeding or considering maternity may need to delay attending the diagnostic test because the test involves exposure to radiation.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The potential equality issues will be considered by committee during decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

The potential equality issues have been included in the equalities section of the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues have been identified during the scoping process.

Approved by Associate Director (name): Rebecca Albrow

Date: 11/11/20